-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sirnaomics Ltd.
Sirnaomics' proprietary GalNAc-RNAi therapy delivery platform, GalAhead™, relies on a unique RNA structure that can "silence" single or multiple mRNA targets, specifically two key technology components in its structure, mxRNA™ (miniaturized RNAi triggers) and muRNA™ (Multi-Unit RNAi Trigger)
Complement-mediated diseases are one of Sirnaomics' core therapeutic areas for products based on the GalAhead delivery platform
"We are very pleased with the performance of the company's proprietary GalAhead delivery platform, which enables us to rapidly, reproducibly and predictably expand and advance our pipeline of products based on this new technology," said Dr.
"We are encouraged by the pace of expansion of the pipeline based on the GalAhead delivery platform